Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Asset Writedowns and Impairment (2018 - 2020)

Historic Asset Writedowns and Impairment for Medifast (MED) over the last 5 years, with Q4 2020 value amounting to $48000.0.

  • Medifast's Asset Writedowns and Impairment fell 8881.12% to $48000.0 in Q4 2020 from the same period last year, while for Dec 2020 it was $893000.0, marking a year-over-year increase of 568.05%. This contributed to the annual value of $556000.0 for FY2020, which is 8471.69% down from last year.
  • Latest data reveals that Medifast reported Asset Writedowns and Impairment of $48000.0 as of Q4 2020, which was down 8881.12% from $429000.0 recorded in Q4 2019.
  • Over the past 5 years, Medifast's Asset Writedowns and Impairment peaked at $429000.0 during Q4 2019, and registered a low of $48000.0 during Q4 2020.
  • In the last 3 years, Medifast's Asset Writedowns and Impairment had a median value of $416000.0 in 2018 and averaged $297666.7.
  • As far as peak fluctuations go, Medifast's Asset Writedowns and Impairment skyrocketed by 312.5% in 2019, and later plummeted by 8881.12% in 2020.
  • Quarter analysis of 3 years shows Medifast's Asset Writedowns and Impairment stood at $416000.0 in 2018, then rose by 3.12% to $429000.0 in 2019, then tumbled by 88.81% to $48000.0 in 2020.
  • Its last three reported values are $48000.0 in Q4 2020, $429000.0 for Q4 2019, and $416000.0 during Q4 2018.